New evidence in severe pneumonia: meropenem-vaborbactam.

• Autores: María Forteza Guillot, María Martín Cerezuela, Paula Ramírez
• Localización: Revista Española de Quimioterapia, ISSN-e 0214-3429, Vol. 35, Nº Extra 1, 2022, págs. 43-45
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • The appearance and spread of new mechanisms of bacterial resistance to antibiotics is a serious health problem. One of the most difficult resistance mechanisms to treat is the production of carbapenemases. Carbapenemase KPC is one of those mechanisms with few therapeutic options. Meropenem-vaborbactam has shown great efficacy against this type of microorganism, both from a clinical and microbiological point of view. Its good pharmacokinetics, including in the lung, and its safety profile make meropenem-vaborbactam an excellent therapeutic option. Finally, the absence of resistance genesis during treatment seems to indicate that its efficacy will be long-lasting.